Fennec Pharmaceuticals Inc (FRX.TO) has seen notable price movement this week, driven by recent financial results and business updates.
Fennec Pharmaceuticals Inc has experienced a strong performance this week, with shares rising by 9.75% on Thursday alone. The stock has gained 3.79% over the past week and shows an impressive 63.30% increase year-to-date. This surge follows the announcement of strong financial results and updates that have captured the attention of investors.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$487.43M
52W high
$17.64
52W low
$7.59
1W change
-6.46%
Beta
1.23
Analyst Price Targets
Based on analyst covering FRX · as of Sep 17, 2026
Wall Street analysts forecast FRX stock price to rise 573.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+573.2% Upside
Current Price
C$13.90
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
58.3%
Annualized
90-Day Vol
60.1%
Annualized
Trend (90d)
-26.1%
Annualized drift
90d Mean
C$12.66
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$13.48 | C$11.02 – C$16.48 |
| 60 trading days | C$13.06 | C$9.83 – C$17.36 |
| 90 trading days | C$12.66 | C$8.94 – C$17.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Fennec's recent financial performance and business updates indicate a positive trajectory for the company, particularly with the growth in PEDMARK® sales. However, investors should consider the company's ongoing challenges, including negative profit margins and the need for continued market acceptance of its products.
Fennec Pharmaceuticals Reports 50% Year-over-Year Growth in Product Sales
With net PEDMARK® product sales reaching $44.6 million, Fennec Pharmaceuticals has demonstrated substantial growth, marking a crucial milestone for the company.
Bull case
Fennec Pharmaceuticals has reported record annual revenues, driven by significant growth in PEDMARK® product sales. The company shows resilience and potential for future profitability, especially with positive results from clinical studies.
Bear case
Despite the positive sales growth, Fennec continues to operate at a loss, with negative profit margins and return on equity. Investors should remain cautious about the sustainability of this growth and the company's ability to achieve profitability.
Price Action Overview
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$17.00 on Thursday, reflecting a remarkable increase of 9.75% for the day. The stock has performed well over the past week, with a total increase of 3.79%, and has shown significant resilience with a year-to-date performance of 63.30%.
Recent Company News
Advertisement
Fennec Pharmaceuticals recently reported its financial results for 2025, highlighting a record annual revenue driven by net PEDMARK® product sales of $44.6 million, representing a 50% year-over-year growth. Additionally, the company completed an oversubscribed $42 million equity offering and reported positive topline results from an investigator-initiated clinical study of PEDMARK® in Japan.
Technical Picture
Currently, Fennec's stock is trading well above its 50-day moving average of C$14.78, indicating a bullish trend with a 15.0% premium. The stock is also significantly above its 200-day moving average of C$11.72, showing a 45.1% increase. The 52-week range for FRX.TO is C$7.59 to C$17.64, meaning the stock is trading at 94% of its range. The beta of 1.07 suggests that the stock is slightly more volatile than the market, and recent trading volume has been lower than average, with 604 shares traded compared to a 20-day average of 839 shares.
Insider Activity
There are currently no reported insider activities for Fennec Pharmaceuticals that would provide additional insight into the company's stock movements.
Final Thoughts
Fennec Pharmaceuticals Inc closed at C$17.00, reflecting a 9.75% increase for the day. The company's recent financial results and growth in product sales paint a promising picture for investors, although caution is advised due to ongoing losses.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
